Contribution of pharmacodynamics in the choice of antimicrobials in the exacerbation of COPD;Contribución de la farmacodinamia en la elección del antimicrobiano para las exacerbaciones de la EPOC

Revista Espanola de Quimioterapia

Volumn 19, Issue 3, 2006, Pages 220-230

  Eiros Bouza, José Ma ^a,d   Valdes Verelst L ^b   Bachiller Luque, M R ^c  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b GLAXOSMITHKLINE   (Spain)

^c Centro de Salud Pilarica   (Spain)

^d UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEFACLOR; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; PENICILLIN G; ANTIINFECTIVE AGENT;

BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG EFFECT; ERADICATION THERAPY; HAEMOPHILUS INFLUENZAE; HUMAN; INFLUENZA; MAXIMUM ALLOWABLE CONCENTRATION; REVIEW; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; CLINICAL TRIAL;

ANTI-INFECTIVE AGENTS; CLINICAL TRIALS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 33750896641     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Annunciato, P.W., Powell, K.R. Infections of the upper respiratory tract. En: Reese, R.E., Betts, R.F. (Eds.). A practical approach to infectious diseases, 4th ed. Little Brown & Company, New York 1996; 211-239.
2. Macfarlane, J.T., Colville, A., Guion, A., Macfarlane, R.M., Rose, D.H. Prospective study on aetiology and outcome of adult lower-respiratory tract infections in the community. Lancet 1993; 341: 511-514.
3. Graham, N.M.H. The epidemiology of acute respiratory infections in children and adults: A global perspective. Epidemiol Rev 1990; 12: 149-178.
4. Mogyoros, M. Challenges of managed care organizations in treating respiratory tract infections in an age of antibiotic resistance. Am J Man Care 2001; 7 (Suppl. 6): 163-169.
5. Sobradillo, V., Miravitlles, M., Gabriel, R. y cols. Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest 2000; 118: 981-989.
6. Miratvilles, M., Guerrero, T., Mayordomo, C. y cols. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: A multiple logistic regression analysis. Respiration 2000; 67: 495-501.
7. Gompertz, S., Bayley, D.L., Hill, S.L., Stockley, R.A. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 2001; 56: 36-41.
8. Miravitlles, M. Fracaso en el tratamiento de las agudizaciones de la enfermedad pulmonar obstructiva crónica. Factures de riesgo e importancia clínica. Med Clin (Barc) 2002; 119: 304-314.
9. Adams, S.G., Melo, J., Luther, M., Anzueto, A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000; 117: 1345-1352.
10. Dewan, N.A., Rafique, S., Kanwar, B. y cols. Acute exacerbation of COPD: Factors associated with poor treatment outcome. Chest 2000; 117: 662-671.
11. Miravitlles, M., Murio, C., Guerrero, T., Gisbert, R., DAFNE Study Group. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121: 1449-1455.
12. Donaldson, G.C., Seemungal, T.A.R., Jeffries, D.J. y cols. Effect of environmental temperature on symptoms, lung function and mortality in COPD patients. Eur Resp J 1999; 13: 844-849.
13. Sheti, S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000; 117: 380S-385S.
14. Boughman, R.P., Pina, E. Infections in acute exacerbations of chronic bronchitis: What are they and how do we know? Sem Resp Crit Care Med 2000; 21: 87-96.
15. Miratvilles, M., Espinosa, C., Fernández-Laso, E. y cols. Relationship between bacterial flora in sputum and functional impairment in patiens with acute exacerbations of COPD. Chest 1999; 116: 40-46.
16. Ball, P., Harris, J.M., Lowson, D. y cols. Acute infective exacerbations of chronic bronchitis. Q J Med 1995; 88: 61-68.
17. Eller, J., Ede, A., Schaberg, T., Niederman, M.S., Mauch, H., Lode, H. Infective exacerbations of chronic bronchitis: Relation between bacteriological etiology and lung function. Chest 1998; 113: 1542-1548.
18. Monsó, E., García-Aymerich, J., Soler, N. y cols. Bacterial infection in exacerbated COPD with challenges in sputum characteristics. Epidemiol Infect 2003; 131: 799-804.
19. Ochoa, C., Eiros, J.M., Inglada, L., Vallano, A., Guerra, L. Assessment of antibiotic prescription in acute respiratory infections in adults. J Infect 2000; 41: 73-83.
20. Pastor García, E., Eiros Bouza, J.M., Mayo Iscar, A. Análisis comparativo de indicadores en los estudios de utilización de medicamentos. Medifam 2002; 12: 7-12.
21. Eiros Bouza, J.M. Introducción. En: Guia de buena práctica clínica en infecciones respiratorias de las vías bajas. Organización Médica Colegial de España. Ministerio de Sanidad y Consume. IM&C, Madrid 2005; 11-12.
22. Felmingham, D., Grünenberg, R.N., Alexander Project Group. The Alexander Project 1996-1997: Latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000; 45: 191-203.
23. Llor, C., Cots, J.M., Boada, A. y cols. Variabilidad de la prescripción de antibióticos en infecciones del tracto respiratorio en dos países europeos. Enferm Infecc Microbiol Clin 2005; 23: 598-604.
24. Burgess, D.S. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest 1999; 115 (Suppl. 3): 19-23.
25. Auckenthaler, R. Pharmacokinetics and pharmacodynamics of oral beta-lactam antibiotics as a two-dimensional approach to their efficacy. J Antimicrob Chemother 2002; 50 (Suppl.): 13-17.
26. Peric, M., Browne, F.A., Jacobs, M.R., Appelbaum, P.C. Activity of nine oral agents gram-positive and gram-negative bacteria encountered in community-acquired infections: Use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents. Clin Ther 2003; 25: 169-177.
27. Aguado-García, J.M., Martín-Herrero, J.E., Lumbreras-Bermejo, C. Resistencias bacterianas y farmacodinamia como bases de la prescripción de antibióticos en infecciones respiratorias. Enferm Infecc Microbiol Clin 2004; 22: 230-237.
28. DeRyke, C.A., Lee, S.Y., Kuti, J.L., Nicolau, D.P. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: Impact on the development of resistance. Drugs 2006; 66: 1-14.
29. Ochoa Sangrador, C., Brezmes Valdivieso, M.F., Eiros Bouza, J.M. Sistemas de clasificación de patientes. JANO 1998; 1276: 114-121.
30. Ausina Ruiz, V., Prats Pastor, G. Principales grupos de seres vivos con capacidad patógena para el hombre. En: Ausina Ruiz, V., Moreno Guillén, S. (Eds.). Tratado SEIMC de Enfermedades Infecciosas y Microbiología Clínica. Médica Panamericana, Madrid 2006; 1-18.
31. Cunha, B.A. The clinical significance of fever patterns. Infect Dis Clin North Am 1996; 10: 33-44.
32. Eiros, J.M., Hernández, B., Landínez, R., Fernández Calvo, J. Infecciones en el paciente neutropénico. Forhos 2000; 3: 5-15.
33. Eiros Bouza, J.M., Martínez, P., Ortiz de Lejarazu, R. Procesamiento de muestras clinicas para el análisis microbioló gico. Técnicas de Laboratorio 1998; 229: 117-123.
34. Llor, C. La atención primaria debe avanzar con las técnicas de diagnóstico rápido. Enferm Infecc Microbiol Clin 2006; 24: 285-286.
35. Llor, C. Consideraciones a la hora de la prescripción antibiótica en atención primaria. Med Clin (Barc) 2004; 5: 52-57.
36. Granizo, J.J., Aguiiar, L., Casal, J., Garcia Rey, C., Dal-Ré, R., Baquero, F. Streptococcus penumoniae resistance to erythromicin and penicillin and relation to macrolide and betalactam consumption in Spain (1979-1997). J Antimicrob Chemother 2000; 767-773.
37. Pérez Trallero, E., Fernández Mazarrasa, C., García Rey, C. y cols. Antimicrobial susceptibilities of 1684 Streptococcus penumoniae and 2039 Streptococcus pyogenes isolates and their ecological relationships: Results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 2001; 45: 3334-3340.
38. Fenoll, A., Asensio, G., Jado, I. y cols. Antimicrobial susceptibility and pneumococcal serotypes. J Antimicrob Chemother 2002; 50: 13-19.
39. García Rodríguez, J.A., Muñoz, J.L. Etiología de la infección respiratoria. Med Clin (Barc) 2004; 5: 2-5.
40. Pérez Trallero, E., García de la Fuente, C., García Rey, C. y cols. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005; 49: 1965-1972.
41. De la Campa, A., Balsalobre, L., Ardanuy, C., Fenoll, A., Pérez Trallero, E., Liñares, J. Fluorquinolone resistance in penicillin-resistant Streptococcus penumoniae clones, Spain. Emerg Infect Dis 2004; 10: 1751-1759.
42. Hyatt, J.M., McKinnon, P.S., Zimmer, G.S., Schentag, J.J. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 1995; 28: 143-160.
43. Craig, W.A. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10.
44. Klugman, K.P. Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections. Eur Respir J 2002; 36 (Suppl.): 3-8.
45. Jacobs, M.R. How can we predict bacterial eradication? Int J Infect Dis 2003; 7 (Suppl. 1): 13-20.
46. Marchant, C.D., Carlin, S.A., Johnson, C.E., Shurin, P.A. Measuring the comparative efficacy of antibacterial agents for acute otitis media: The "Pollyanna phenomenon". J Pediatr 1992; 120: 72-77.
47. Marcos, M.A., Camps, M., Pumarola, T. y cols. The role of viruses in the aetiology of community-acquired pneumonia in adults. Antivir Ther 2006; 11: 351-359.
48. Haldar, S.M., O'Gara, P.T. Infective endocarditis: Diagnosis and management. Nat Clin Pract Cardiovasc Med 2006; 3: 310-317.
49. Van de Beek, D., De Gans, J., Spanjaard, L., Weisfelt, M., Reitsma, J.B., Vermeulen, M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004; 351: 1849-1859.
50. Bisno, A.L., Gerber, M.A., Gwaltney, J.M., Kaplan, E.L., Schwartz, R.H. Diagnosis and management of group A Streptococcal pharyngitis: A practice guideline. Clin Infect Dis 1997; 25: 574-583.
51. Kaplan, E.L., Johnson, D.R. Unexplained reduced microbiological efficacy of intramuscular benzathine penicillin G and of oral penicillin in eradication of group A Streptococci from children with acute pharyngitis. Pediatrics 2001; 108: 1180-1186.
52. Portier, H., Filipecki, J., Weber, P., Goldfarb, G., Lethuaire, D., Chauvin, J.P. Five day clarithromycin modified release versus 10 day penicillin V for group A streptococcal pharyngitis: A multicentre, open label, randomised study. J Antimicrob Chemother 2002; 49: 337-344.
53. Murdoch, D.R. Molecular genetic methods in the diagnosis of lower respiratory tract infections. APMIS 2004; 112: 713-727.
54. Creer, D.D., Dilworth, J.P., Gillespie, S.H. y cols. Aetiological role of viral and bacterial infections in acute adult lower respiratory tract infection (LRTI) in primary care. Thorax 2006; 61: 75-79.
55. Pechère, J.C., Lacey, L. Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 2000; 45: 19-24.
56. Ball, P., Baquero, F., Cars, O. y cols. Antibiotic therapy of community respiratory tract infectons: Strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002; 49: 31-40.
57. Destache, C.J., Dewan, N., O'Donohoue, W.J., Campbell, C.J., Angelilio, V.A. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 43 (Suppl. A): 107-113.
58. Weiss, K., Restieri, C., Gauthier, R. y cols. A nosocomial outbreak of fluorquinolone-resistant Streptococcus pneumoniae. Clin Infect Dis 2001; 33: 517-522.
59. Dunbar, L.M. Current issues in the manegement of bacterial respiratory tract disease: The challenge of antibacterial resistance. Am J Med Sci 2003; 326: 360-368.
60. Martínez, F.J. Acute exacerbation of chronic bronchitis: Expanding shot-course therapy. Int J Antimicrob Agents 2005; 26 (Suppl. 3): 156-163.
61. Soriano, F., Parra, A., Cenjor, C. y cols. Role of Streptococcus pneumoniae and Haemophilus influenzae in the development of acute otitis media and otitis media with effusion in a gerbil model. J Infect Dis 2000; 181: 646-652.
62. Dagan, R., Klugman, K.P., Craig, W.A., Baquero, F. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001; 47: 129-140.
63. Soriano, F. Aspectos farmacocinéticos y farmacodinámicos para la lectura interpretada del antibiograma. Enferm Infecc Microbiol Clin 2002; 20: 407-411.
64. Zelenistsky, S.A., Ariano, R.E., Iacovides, H., Sun, S., Harding, G.K. AUC (0-t)/MIC is a continuos index offluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. J Antimicrob Chemother 2003; 51: 905-911.
65. Stass, H., Dalhoff, A. The integrated use of phahmacokinetic and pharmacodynamic models for the definition of breakpoints. Infection 2005; 33 (Suppl. 2): 29-35.
66. Wilkinson, G.R. Pharmacokinetics: The dynamics of drug absorption, distribution and elimination. En: Hardman, J.G., Limbierd, L.E. (Eds.). Goodman and Gilman's. The pharmacological Basis of Therapeutics, 9th ed. McGraw Hill, New York 2001; 3-30.
67. a ed. McGraw Hill, México 2005; 14-29.
68. Jacobs, M.R., Dagan, R. Antimicrobial resistance among pediatric respiratory tract infections: Clinical challenges. Semin Pediatr Infect Dis 2004; 15: 5-20.
69. Calbo, E., Garau, J. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections. Respiration 2005; 72: 561-571.
70. Rybak, M.J. Pharmacodynamics: Relation to antimicrobial resistance. Am J Med 2006; 119 (6 Suppl. 1): 37-44.
71. a ed. McGraw Hill, México 2005; 884-902.
72. Firsov, A.A., Zinner, S.H., Vostrov, S.N., Portnoy, Y.A., Lubenko, I.Y. AUC/MIC relationships to different endpoint of the antimicrobial effect: Multiple-dose in vitro simulations with moxifloxacin and levofloxacin. J Antimicrob Chemother 2002; 50: 533-539.
73. Jacobs, M.R. Optimization of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 2001; 7: 589-596.
74. Palavecino, E.L. The crisis of resistant pathogens in respiratory tract infections-Use of pharmacodynamic principles. Am J Manag Care 2001; 7 (Suppl. 6): 170-177.
75. Appelbaum, P.C. Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus penumoniae. Clin Infect Dis 2000; 31 (Suppl. 2): 29-34.
76. Jacobs, M.R. Building in efficacy: Developing solutions to combat drug-resistant S. pneumoniae. Clin Microbiol Infect 2004; 10 (Suppl. 2): 18-27.
77. Burgess, D.S. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clin Infect Dis 2005; 40 (Suppl. 2): 99-104.
78. Liu, P., Rand, K.H., Obermann, B., Derendorf, H. Pharmacokinetic- pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in vitro kinetic models. Int J Antimicrob Agents 2005; 25: 120-129.
79. Schentag, J.J. Antimicrobial action and pharmacokinetics/ pharmacodynamics: The use of AUIC to improve efficacy and avoid resistance. J Chemother 1999; 11: 426-439.
80. Rodvold, K.A. Pharmacodynamics of antiifective therapy: Taking what we know to the patient's bedside. Pharmacotherapy 2001; 21: 319S-330S.
81. Gunderson, B.W., Ross, G.H., Ibrahim, K.H., Rotschafer, J.C. What doo we really know about antibiotic pharmacodynamics? Pharmacotherapy 2001; 21: 302S-318S.
82. Klutman, N.B. Selecting antibiotics based on pharmacokinetic and pharmacodynamic principles. Pharm Pract Mang Q 1996; 16: 9-12.
83. Clinical Laboratory Standars Institute. Performance standards for antimicrobial susceptibility testing; 15th informational supplement. NCCLS Document M100-S15. CLSI, Wayne, PA, USA 2005.
84. Soriano, F., Aguilar, L., Ponte, C. In vitro antibiotic sensitivity testing breakpoints and therapeutic activity in induced infections in animal models. J Chemother 1997; 9 (Suppl. 1): 36-46.
85. Aguilar, L., Giménez, M.J. The use of efficacy animal models in breakpoint determination. Rev Esp Quimioterap 1999; 12: 149-151.
86. Antimicrobial Susceptibility Testing: BSAC Working Party Report. J Antimicrob Chemother 2001; 48 (Suppl. 1): 1-102.
87. Arnold, S.R., Strauss, S.E. Interventions to improve antibiotic prescribing practices in ambulatory care. Cocnrane Database Syst Rev 2005; 4: CD003539.
88. DeRyke, C.A., Maglio, D., Nicolau, D.P. Defining the need for new antimicrobials: Clinical and economic implications of resistance in the hospitalised patient. Expert Opin Pharmacother 2005; 6: 873-889.
89. DeRyke, C.A., Lee, S.Y., Kuti, J.L., Nicolau, D.P. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: Impact on the development of resistance. Drugs 2006; 66: 1-14.
90. Blondeu, J.M., Hansen, G., Metzler, K., Hedlin, P. The role of PK/PD paramenters to avoid selection and increase of resistance: Mutant prevention concentration. J Chemother 2004; 16 (Suppl. 3): 1-19.
91. Low, D.E. The era of antimicrobial resistance-implications for the clinical laboratory. Clin Microbiol Infect 2002; 8 (Suppl. 3): 9-20.
92. Picazo, J.J., Betriu, C., Rodriguez-Avial, I., Culebras, E., Gómez, M., Grupo VIRA. Vigilancia de resistencias a los antimicrobianos: Estudio VIRA 2004. Enferm Infecc Microbiol Clin 2004; 22: 517-525.
93. Schaper, K.J., Schubert, S., Dalhoff, A. Kinetics and quantification of antibacterial effects of beta-lactams, macrolides, and quinolones against gram-positive and gram-negative RTI pathogens. Infection 2005; 33 (Suppl. 2): 3-14.
94. Soriano, F. Importancia de los parámetros farmacocinéticos y farmacodinámicos en la elección del tratamiento antimicrobiano de la infección respiratoria. Med Clin (Barc) 2004; 5: 6-11.
95. Andes, D. Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2001; 14: 165-172.
96. Gums, J.G. NCCLS perspectives in changing susceptibility breakpoints for antimicrobial drugs. Int J Antimicrob Agents 2003; 22 (Suppl. 1): 3-13.
97. Drlica, K., Zhao, X., Blondeau, J.M., Hesje, C. Low correlation between MIC and mutant prevention concentration. Antimicrob Agents Chemother 2006; 50: 403-404.
98. Snow, V., Lascher, S., Mottur-Pilson, C., Joint Expert Panel on COPD of the American College of Chest Physicians and the American College of Physicians-American Society of Internal Medicine. The evidence base for management of acute exacerbations of COPD: Clinical practice guideline, part 1. Chest 2001; 119: 1185-1189.
99. Balter, M.S., La Forge, J., Low, D.E., Mandell, L., Grossman, R.F., Chronic Bronchitis Working Group; Canadian Thoracic Society; Canadian Infectious Disease Society. Canadian guidelines for the management of acute exacerbations of chronic bronchitis: Executive summary. Can Respir J 2003; 10: 248-258.
100. Miravitlles, M., Murio, C., Guerrero, T. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group. Eur Respir J 2001; 17: 928-933.
101. Miravitlles, M., Torres, A. Antibiotics in exacerbations of COPD: Lessons from the past. Eur Respir J 2004; 24: 896-897.
102. White, A.J., Gompertz, S., Bayley, D.L. y cols. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003; 58: 680-685.
103. Patel, I.S., Seemungal, T.A., Wilks, M. y cols. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002; 57: 759-764.
104. World Health Organization. World Health Organization report on infectious diseases 2000: Overcoming antimicrobial resistance. Available at: http://www.who.int/infectious-diseasereport/2000/intro.htm.
105. Martínez, F.J., Anzueto, A. Appropriate outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Am J Med 2005; 118 (Suppl. 7A): 39S-44S.
106. Giblin, T.B., Sinkowitz-Cochran, R.L., Harris, P.L. y cols., CDC Campaign to Prevent Antimicrobial Resistance Team. Clinicians' perceptions of the problem of antimicrobial resistance in health care facilities. Arch Intern Med 2004; 164: 1662-1668.
107. Giménez, M.J., Gómez-Lus, M.L., Valdés, L., Aguilar, L. Situación de la cefalosporina oral de tercera generación cefditoreno pivoxil en el tratamiento de la infección comunitaria del adulto. Rev Esp Quimioterap 2005; 18: 210-216.
108. Guillemot, D., Carbon, C., Balkau, B. y cols. Low dosage and long treatment duration of beta-lactam: Risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998; 279: 365-370.
109. Ficha técnica de Spectracef. http://sinaem.agemed.es: 83/presentación/principal.asp "visitado el 3 de agosto de 2006".
110. Soriano, F., Granizo, J.J., Fenoll, A. y cols. Antimicrobial resistance among clinical isolates of Streptococcus penumoniae isolated in four Southern European countries (ARISE project) from adult patients: Results from the cefditoren surveillance program. J Chemother 2003; 15: 107-112.
111. Soriano, F., Granizo, J.J., Coronel, P. y cols. Antimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European countries. The ARISE project. Int J Antimicrob Agents 2004; 23: 296-299.
112. Prieto, J., Giménez, M.J., Aguilar, L. Implicaciones de los paramétros farmacodinámicos en el tratamiento antibiótico del paciente con infección respiratoria del tracto inferior. Med Clin (Barc) 2006; Monografía 7: 12-16.
113. Martínez, F.J. Acute bronchitis: State of the art diagnosis and therapy. Compr Ther 2004; 30: 55-69.
114. Marco, F., García de Lomas, J., García-Rey, C. y cols. Antimicrobial susceptibilities of 1,730 Haemophilus influenzae respiratory tract isolates in Spain in 1998-1999. Antimicrob Agents Chemother 2001; 45: 3226-3228.